Evidence map›Paper›PMID 41013996›Full record

ArticleInternational journal of immunopathology and pharmacology

Identification of prognostic biomarkers for hepatocellular carcinoma based on the m6A RNA modification.

Jiachun Sun, Ziyi Xu, Yitao Fan, Bo Sun, Weizheng Wang, Mengjuan Xuan, Penghui Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiachun SunHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, Henan, China.
Ziyi XuHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, Henan, China.
Yitao FanHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, Henan, China.
Bo SunHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, Henan, China.
Weizheng WangHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, Henan, China.
Mengjuan XuanDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.ORCID 0009-0002-9732-2104
Penghui LiDepartment of Gastrointestinal surgery, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this study was to identify the prognostic biomarkers for hepatocellular carcinoma (HCC) by analyzing the N6-methyladenosine (m6A) RNA modification. HCC is a complex malignant tumor induced by various pathogenic factors. m6A RNA modification and its regulators influence the tumorigenesis and advancement of HCC. RNA sequencing and clinical data were extracted from the TCGA-LIHC and ICGC-LIRI-JP database. Single-cell RNA sequencing data were processed using Seurat and Harmony packages. ConsensusClusterPlus identified molecular subtypes, and ssGSEA quantified m6A regulator-related gene sets. Differentially expressed genes were analyzed, followed by the establishment of a risk model. qRT-PCR validated mRNA expression in Huh7, Hep 3B, and Hep G2 cells and normal hepatocytes. Four molecular subtypes based on m6A regulator transcriptional profiles of m6A regulators were identified, each exhibiting unique clinical, prognostic, and pathway characteristics. A robust risk model distinguished the high- and low-risk groups, revealing obvious differences in immune cells infiltration and chemotherapeutic drug sensitivity. qRT-PCR confirmed significant differential expression of key genes (TRNP1, KIF20A, and CFRHR3) in HCC cell lines and normal hepatocytes. In conclusion, the established risk model may serve as a perspective tool for prognostic prediction, and provide insights into the functions of m6A involved in HCC.

Indexed as

AdenosineBiomarkers, TumorCarcinoma, HepatocellularLiver NeoplasmsCell Line, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHep G2 CellsHumansPrognosisRNA MethylationAdenosineBiomarkers, TumorN-methyladenosinehepatocellular carcinomaLASSON6-methyladenosineprognosisrisk modelRNA modification

Identifiers

PMID41013996
PMCPMC12476503

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.